Why Publish in JID?

Broad Scope

The Journal of Investigative Dermatology (JID) publishes high impact reports describing original research related to all aspects of cutaneous biology and skin disease. The JID places a high priority on publication of new insights into basic cutaneous biology, disease pathogenesis, and treatment. Descriptions of important findings that result from basic, translational, or clinical research are appropriate for submission. Clinical research can include, but is not limited to, interventional trials, genetic studies, epidemiology, and health services research.

Global Reach and Indexing

Through its publishing partner, Elsevier, JID is able to reach academic, corporate, and government institutions and consortia throughout the world. JID boasts an average of over 74,000 page views across www.JIDonline.org per month. In addition, our social media presence allows us to help authors to reach readers through a variety of online venues. JID is included in the leading abstracting and indexing services including ISI, MEDLINE, EMBASE and BIOSIS. Extensive reference linking to MEDLINE, ISI, and others via services such as Crossref and DOI (digital object identifier) numbers provides seamless online linking between articles and databases.

Expert Review and Timely Decisions

JID provides submitting authors an expert, thorough, and timely review of all peer-reviewed submissions. Our editorial board is composed of internationally recognized experts in the wide range of subject areas comprising the field of investigative dermatology. In general, submissions are reviewed by two external reviewers and two editorial board members, and on average submissions receive a decision within 30 days of submission. Those submissions deemed by the editorial board to be inappropriate for the journal are generally rejected without external review within 5 days of submission. In general, authors are provided with constructive comments for their consideration.

Fast Publication

JID publishes accepted Original Articles and Letters to the Editor online within one week of receipt of all publication materials. By publishing and indexing accepted articles in their manuscript form, JID makes the work available to readers immediately. Once the article has been copyedited, typeset, and proofed, that version replaces the manuscript form of the article online. Both versions bear the same DOI, allowing articles to be referenced as soon as they appear in the manuscript form and ensuring that references to the material will be consistent.

Supplementary Materials and Interactive Features

Authors are invited to submit supporting material such as video for publication online. Online supplementary material gives articles greater depth, making them more useful to readers. Online supplementary material makes the most of the Web as a delivery platform and can often give articles greater depth, making them more useful to readers. New Content Innovation features by Elsevier, such as Virtual Microscope and Data Visualization tools, allow authors to maximize the data they publish and allow readers to interact with those data in more meaningful ways. For examples of recent JID quizzes, please see https://www.jidonline.org/jid_snap_poll_139_2 and https://www.jidonline.org/rtms139_2 .

Authors Retain Copyright of their Work

Authors publishing in JID retain copyright in their articles and grant the Society for Investigative Dermatology an exclusive license to publish their work. In return, authors can reuse their own articles in any future published work and post them on their own website (https://www.elsevier.com/about/policies/copyright). For open access articles: Authors will be asked to complete an 'Exclusive License Agreement' (for more information see https://www.elsevier.com/authors/journal-authors/open-access). Permitted third party reuse of open access articles is determined by the author's choice of user license (see https://www.elsevier.com/openaccesslicenses). Authors should cite the JID publication (including its DOI) and link to it from the new article.


Authors are encouraged to submit their version of the accepted, peer-reviewed manuscript to their funding body's archive, for public release six months after publication. In addition, authors are encouraged to archive their version of the manuscript in their institution's repositories (as well as on their personal web sites), also six months after the original publication. Authors should cite the publication reference and DOI number on any deposited version and provide a link from it to the published article on the Elsevier website. This policy complements the policies of the US National Institutes of Health, the Wellcome Trust and other research funding bodies around the world.

Automated Deposition

Submissions funded by the US National Institutes of Health (NIH), Howard Hughes Medical Institute (HHMI), and the Wellcome Trust will be deposited in the appropriate repository on behalf of the authors, provided this service is requested of the publisher during article production.

Open Access

Authors of research articles can opt to pay an article processing charge for their accepted articles to be published open access online immediately upon publication. By paying this charge, authors are also permitted to post the final, published PDF of their article on a website, institutional repository or other free public server immediately upon publication. These publishing policies ensure that authors can fully comply with the public access requirements of the major funding bodies worldwide. Please visit www.sherpa.ac.uk for more information. All other JID material is made available free online one year after publication.